Lots of room just to catch up with a fair valuationPrice tag is rarely an issue. 2023 is going to be much batter than 2022 in the M&A space, as per PwC, EY and many experts in the industry.
Below are examples, just to give some a sense of valuation. I'm not saying that this will be our valuation tomorrow morning with only one indication. But with 3 major ones (NMIBC, Ph. 1b in GBM and NSCLC) and a clinical data to demonstrate that PDT delivers better efficacy than anything else on the market when it comes to destroying solid tumors, then we could become a darling one.
The examples below are also to show that our current valuation (65M$US) is low, when we're 50% into a pivotal Ph. 2 that could make us the next SOC in NMIBC even in early-stage settings and allow us to displace the unreliable BCG. We have ample room to grow. Easily 10x our current 65M$US just to catch up, if we get a minimum of fair recognition.
The year’s largest deal at deadline was Amgen’s $27.8 billion purchase of Horizon Therapeutics, announced December 12, followed by Pfizer’s $11.6 billion purchase of Biohaven Pharmaceuticals, completed October 3.
- “There is an urgent unmet need for a non-surgical alternative to radical cystectomy in this patient population and we are firmly committed to developing the next standard of care for NMIBC,” Dr. Mandel contends.
“If we succeed with an alternative treatment to radical cystectomy for NMIBC, the market potential could be valued in the billions of dollars annually,” Dr. Mandel suggests.